Development of [F-18]-Labeled Amyloid Imaging Agents for PET
The applicant proposes to design and synthesize a series of fluorine-18-labeled radiopharmaceuticals to be used as amyloid imaging agents for positron emission tomography (PET). The investigators will conduct comprehensive iterative in vitro and in vivo studies based upon well defined acceptance criteria in order to identify lead agents suitable for human studies. The long term goals are to apply the selected radiotracers as potential diagnostic agents of Alzheimer's disease (AD), as surrogate markers of amyloid in the brain to determine the efficacy of anti-amyloid therapeutic drugs, and as tools to help address basic scientific questions regarding the progression of the neuropathology of AD, such as testing the "amyloid cascade hypothesis" which holds that amyloid accumulation is the primary cause of AD.
- Research Organization:
- University of Pittsburgh, Pittsburgh, PA
- Sponsoring Organization:
- USDOE - Office of Energy Research (ER)
- DOE Contract Number:
- FG02-03ER63590
- OSTI ID:
- 903085
- Report Number(s):
- DOE/ER/63590; ID: ER63590-1021311-0009485; TRN: US1002546
- Country of Publication:
- United States
- Language:
- English
Similar Records
A New F-18 Labeled PET Agent For Imaging Alzheimer's Plaques
{sup 18}F-desmethoxyfallypride: A fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D{sub 2} receptors